Evidence map›Paper›PMID 40473728›Full record

ArticleScientific reports2025

Correlation between ADGRV1 expression and clinical pathological and prognostic features in breast cancer.

Lili Wang, Jiadi He, Jiaqing Chen, Xueqing Zeng, Wenjie Lu, Yulan Qiu, Meigong Zhong, Qiuli Li, Qisheng Long, Liangliang Ren and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lili WangDepartment of Clinical Pathology, Jiangmen Maternity and Child Health Care Hospital, Jiangmen, 529099, Guangdong, People's Republic of China.
Jiadi HeJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China.
Jiaqing ChenJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China.
Xueqing ZengJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China.
Wenjie LuJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China.
Yulan QiuJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China.
Meigong ZhongDepartment of Pharmacy, Jiangmen Maternity and Child Health Care Hospital, Jiangmen, 529099, Guangdong, People's Republic of China.
Qiuli LiMedical Genetics Center, Jiangmen Maternity and Child Health Care Hospital, Jiangmen, 529099, Guangdong, People's Republic of China.
Qisheng LongDepartment of Breast Surgery, Jiangmen Maternity and Child Health Care Hospital, Jiangmen, 529099, Guangdong, People's Republic of China.
Liangliang RenJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China. renll@mail3.sysu.edu.cn.
Xin ZhangJiangmen Key Laboratory of Precision and Clinical Translation Medicine, Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Central Hospital, Jiangmen, 529030, People's Republic of China.
Yuanzhi LuDepartment of Clinical Pathology, the First Affiliated Hospital of Jinan University, Guangzhou, 510632, Guangdong, People's Republic of China. Yuanzhi.lu@jnu.edu.cn.

Funding

Medical Science Foundation of Jiangmen Central Hospital J202001National Natural Science Foundation of China 82103582Science and Technology Project of Guangdong Province 2021A1515012432
6 · The paper itself

Abstract

Breast cancer, a leading global health threat with rising incidence, demands precision medicine guided by molecular subtyping. ADGRV1, an adhesion G protein-coupled receptor gene implicated in tumorigenesis but unexplored in breast cancer, was investigated using TCGA data (1,231 cases) and a local cohort (408 cases). While ADGRV1 showed no differential expression between tumors and normal tissues (P = 0.210), it was significantly downregulated in basal-like subtypes (P < 0.001). The association between high ADGRV1 expression and poor prognosis remains significant in the overall cohort as well as within individual molecular subtype. Functional enrichment analyses linked ADGRV1 to ribosome suppression, ECM remodeling (positive ECM-receptor interaction), and immunosuppression (negative immune pathway regulation), suggesting its role in tumor metastasis. Drug sensitivity assays demonstrated ADGRV1-high tumors confer resistance to lapatinib, gemcitabine, and 5-fluorouracil, particularly in LumB subtypes. Mechanistically, copy number variations and promoter methylation (Pearson r =-0.45, P < 0.001) regulated ADGRV1 expression, with basal-like tumors showing hypermethylation-associated suppression. These findings position ADGRV1 as a prognostic biomarker and potential therapeutic target, highlighting its dual role in tumor microenvironment modulation and drug resistance.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticReceptors, G-Protein-CoupledBiomarkers, TumorDNA Copy Number VariationsDNA MethylationDrug Resistance, NeoplasmFemaleHumansPrognosisPromoter Regions, GeneticBiomarkers, TumorReceptors, G-Protein-CoupledADGRV1Breast cancerDrug sensitivityImmune microenvironmentMethylationPrognosis

Identifiers

PMID40473728
PMCPMC12141595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.